Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease
news
Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis
Phase 2/3 study did not meet primary or key secondary endpoints; ulviprubart showed a favorable safety and tolerability profile compared to placebo Clinically meaningful slowing of disease progression observed in patients with mild to moderate disease; establishes basis for advancing ulviprubart in this segment of the population Study results to be presented at the 6th
February 24, 2026
Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body MyositisPress Releases
